<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
New fill/finish partnership with BioConnection provides end-to-end drug product development under 1 contract!   Read the press release

1 min read

AGC Biologics Receives Bioprocessing Excellence Award in Japan for Work at Chiba Site

AGC Biologics Receives Bioprocessing Excellence Award in Japan for Work at Chiba Site

Today we announced that we received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.   

The Asia-Pacific Bioprocessing Excellence Awards (ABEA), hosted by IMAPAC, gives recognition to exceptional Asian bioprocessing companies for their achievements over the past year.  AGC Biologics was honored alongside other industry leaders at the 10th Annual Biologics Manufacturing Asia Conference on March 15. 

We are a CDMO in Japan with microbial and mammalian capabilities backed by a global resource and supply chain network. The multipurpose Chiba facility has a highly efficient core structure and gravity-based design enabling it to provide flexibility and produce high-quality work. Our Chiba site has scientific teams with extensive industry experience, established large-scale commercial microbial capabilities, and growing single-use mammalian systems with a high manufacturing success rate. It also benefits from its deep collaboration with our sister locations in Europe and the U.S., which helps provide everything AGC Biologics can offer at this central location in the Asia-Pacific region.  

“AGC Biologics is honored to receive this award showcasing our growing biologics capabilities at our site in Chiba, Japan, and the great work our team members perform every day,” said Jun Takami, General Manager, AGC Biologics Chiba Facility. “Our scientists are experts in tailoring our services to meet our customers' needs. We pride ourselves on developing and supplying multi-language documentation, GMP manufacturing that adheres to our customer’s timelines, and striving to achieve the highest level of global customer satisfaction in everything we do.”

The Chiba site has a very successful microbial project track record, from process development for various expression systems (E. coli, yeast, etc.) to commercial production. The Chiba site has established rapid and robust processes using our platform development method to ensure reliable transfer, verification, and optimization of the customer’s process for mammalian products. Our mammalian-based systems can accommodate virtually any molecule type, including monoclonal antibodies (mAbs), coagulation factors, fusion proteins, and more. 

To learn more about AGC Biologics’ Chiba site and all its capabilities, visit https://www.agcbio.com/facilities/chiba